Skip to content

LEGALIZING CANNABIS LINKED TO LESS OPIOID PRESCRIPTIONS, COULD HELP COMBAT EPIDEMIC, SCIENTISTS SAY

LEGALIZING CANNABIS LINKED TO LESS OPIOID PRESCRIPTIONS, COULD HELP COMBAT EPIDEMIC, SCIENTISTS SAY

There are less opioid prescriptions on average in U.S. states where medical and recreational marijuana are legal, research has revealed.

Access to recreational cannabis in the U.S. was tied with a 11.8 percent lower rate of opioids prescriptions each day, and 4.2 percent for medical marijuana. The authors of the paper published in the Journal of Health Economics said recreational weed laws could make it easier for patients to access the drug, and use it to treat pain and other conditions.

Both types of law also appeared to cut down the total number of patients receiving opioids, as well as the total days opioids were supplied, and the likelihood of a healthcare provider prescribing the painkillers. The study also showed family physicians gave out more opioids than any other healthcare speciality, such as dentists or nurses.

Read Full Article Here

Stories you may be interested in

Arfinn Med March Updates

We are very happy to announce the release of several new functions within the Arfinn Med Platform.  Those include: * Text message updates from patients regarding their treatments * Templating for exam notes  * Updated analytics and dosing reports * Google calendar and Calendly integrations to schedule appointments. Please view the video below for more…
Read More

Norfolk research company plans clinical trials using medical marijuana

Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions. Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer.…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

CEO Spotlight: James West

As a former academic coordinator for the City University of New York Research Foundation and Medgar Evers College, CEO and co-founder of Arfinn Med, James West, has extensive experience in adult education and professional training programming. James put this extensive education to good use when he noticed that there was a direct need for a…
Read More

Medical marijuana: Florida House seeks to intervene in ‘monumental’ case

TALLAHASSEE — Florida House leaders should be able to participate in a lawsuit that could revolutionize the state’s medical marijuana market, a lawyer for the Republican-led chamber told a three-judge panel of the 1st District Court of Appeal Tuesday. But Tampa-based Florigrown argued that legislators instead should concentrate on fixing the law, aimed at carrying…
Read More

New Feature: Calendar Integration

At Arfinn Med, we’re excited to announce the third feature update to join automated text messaging and note templating: calendar integration. With this addition, physicians can now integrate their Google Calendar or Calendy account. The implementation of calendar integration rounds out the Arfinn Med portal, making it a physician’s one-stop-shop EMR tool. How It Works…
Read More

Leave a Comment

You must be logged in to post a comment.